The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model.

Abstract

Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) may account for treatment failure with vancomycin and act as a precursor of vancomycin-intermediate or -resistant S. aureus. The activity of vancomycin was assessed against vancomycinsusceptible, hVISA and VISA strains in a dilutional pharmacokinetic model. Over a 48 h period, total bacteria and cells with a vancomycin-intermediate phenotype were quantified. Total counts of hVISA were reduced by vancomycin in a similar way to a vancomycin-susceptible control. The vancomycin-intermediate sub-population was eradicated from the model within one dose interval. Exposure to low vancomycin concentrations did not result in an increase in the proportion of cells which were vancomycin intermediate. Short-term exposure of hVISA to vancomycin at gradient concentrations did not increase the proportion of cells with vancomycin-intermediate phenotype.

Statistics

0204060'04'06'08'10'12'14'16
Citations per Year

60 Citations

Semantic Scholar estimates that this publication has 60 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Turner2001TheAO, title={The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model.}, author={Jenny J. Turner and Robin A. Howe and Mandy Wootton and Karen E. Bowker and Helene A Holt and Vyvyan C. Salisbury and Peter M . Bennett and Timothy R. Walsh and Alasdair P Macgowan}, journal={The Journal of antimicrobial chemotherapy}, year={2001}, volume={48 5}, pages={727-30} }